Timp2-modified gelatinhydroxyphenylpropionic acid hydrogels reverse enhanced scleral recovery and suppress myopia development in mice

IF 8.7 1区医学 Q1 ENGINEERING, BIOMEDICAL

Materials Today Bio Pub Date : 2025-06-07 DOI:10.1016/j.mtbio.2025.101942

Kaiqi Liu , Ting Li , Lingwen Gu , Zhenyu Jiang , Jing Jiang , Xi Yang , Yang Zhou , Xiao Feng , Qianqian Gong , Lihua Zhao , Yiming Chen , Chao Yang , Tao Jiang

{"title":"Timp2-modified gelatinhydroxyphenylpropionic acid hydrogels reverse enhanced scleral recovery and suppress myopia development in mice","authors":"Kaiqi Liu , Ting Li , Lingwen Gu , Zhenyu Jiang , Jing Jiang , Xi Yang , Yang Zhou , Xiao Feng , Qianqian Gong , Lihua Zhao , Yiming Chen , Chao Yang , Tao Jiang","doi":"10.1016/j.mtbio.2025.101942","DOIUrl":null,"url":null,"abstract":"<div><div>A novel therapeutic strategy for form deprivation myopia (FDM) involving Timp2-modified scleral stem cells (SSC<sup>Timp2</sup>) embedded in gelatin-hydroxyphenylpropionic acid (Gtn-HPA) hydrogel was investigated. Transcriptome and single-cell RNA sequencing analyses identified Timp2 as a crucial factor in FDM progression due to its reduced expression in FDM sclera. The developed SSC<sup>Timp2</sup>-Gtn-HPA hydrogel composite demonstrated excellent biocompatibility, rapid gelation, and degradation properties. <em>In vitro</em> studies showed that SSC<sup>Timp2</sup>-GH promoted human scleral fibroblast (HSF) proliferation, inhibited apoptosis, and prevented differentiation. <em>In vivo</em> experiments in mice showed that SSC<sup>Timp2</sup>-GH effectively regulated ocular parameters, facilitated scleral recovery, and improved FDM conditions. These results highlight the potential of SSC<sup>Timp2</sup>-GH as a promising therapeutic approach for myopia treatment by enhancing scleral recovery.</div></div>","PeriodicalId":18310,"journal":{"name":"Materials Today Bio","volume":"33 ","pages":"Article 101942"},"PeriodicalIF":8.7000,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Materials Today Bio","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590006425005125","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

A novel therapeutic strategy for form deprivation myopia (FDM) involving Timp2-modified scleral stem cells (SSC^Timp2) embedded in gelatin-hydroxyphenylpropionic acid (Gtn-HPA) hydrogel was investigated. Transcriptome and single-cell RNA sequencing analyses identified Timp2 as a crucial factor in FDM progression due to its reduced expression in FDM sclera. The developed SSC^Timp2-Gtn-HPA hydrogel composite demonstrated excellent biocompatibility, rapid gelation, and degradation properties. In vitro studies showed that SSC^Timp2-GH promoted human scleral fibroblast (HSF) proliferation, inhibited apoptosis, and prevented differentiation. In vivo experiments in mice showed that SSC^Timp2-GH effectively regulated ocular parameters, facilitated scleral recovery, and improved FDM conditions. These results highlight the potential of SSC^Timp2-GH as a promising therapeutic approach for myopia treatment by enhancing scleral recovery.

查看原文本刊更多论文

timp2修饰明胶羟基苯基丙酸水凝胶逆转增强巩膜恢复并抑制小鼠近视发展

研究了嵌入明胶-羟基苯基丙酸（Gtn-HPA）水凝胶的timp2修饰巩膜干细胞（SSCTimp2）治疗形式剥夺性近视（FDM）的新策略。转录组和单细胞RNA测序分析发现Timp2是FDM进展的关键因素，因为它在FDM巩膜中的表达减少。开发的SSCTimp2-Gtn-HPA水凝胶复合材料具有良好的生物相容性、快速凝胶化和降解性能。体外研究表明，SSCTimp2-GH促进人巩膜成纤维细胞（HSF）增殖，抑制凋亡，阻止分化。小鼠体内实验表明，SSCTimp2-GH可有效调节眼部参数，促进巩膜恢复，改善FDM病情。这些结果突出了SSCTimp2-GH通过增强巩膜恢复作为一种有希望的近视治疗方法的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Materials Today Bio Multiple-

CiteScore

8.30

自引率

4.90%

发文量

303

审稿时长

30 days

期刊介绍： Materials Today Bio is a multidisciplinary journal that specializes in the intersection between biology and materials science, chemistry, physics, engineering, and medicine. It covers various aspects such as the design and assembly of new structures, their interaction with biological systems, functionalization, bioimaging, therapies, and diagnostics in healthcare. The journal aims to showcase the most significant advancements and discoveries in this field. As part of the Materials Today family, Materials Today Bio provides rigorous peer review, quick decision-making, and high visibility for authors. It is indexed in Scopus, PubMed Central, Emerging Sources, Citation Index (ESCI), and Directory of Open Access Journals (DOAJ).